1.35
Precedente Chiudi:
$1.37
Aprire:
$1.35
Volume 24 ore:
2.67M
Relative Volume:
1.62
Capitalizzazione di mercato:
$82.88M
Reddito:
$5.03M
Utile/perdita netta:
$-185.41M
Rapporto P/E:
-0.4369
EPS:
-3.09
Flusso di cassa netto:
$-139.79M
1 W Prestazione:
+4.65%
1M Prestazione:
-8.78%
6M Prestazione:
-90.22%
1 anno Prestazione:
-88.91%
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Nome
Pliant Therapeutics Inc
Settore
Industria
Telefono
650-481-6770
Indirizzo
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta PLRX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
PLRX
Pliant Therapeutics Inc
|
1.35 | 79.19M | 5.03M | -185.41M | -139.79M | -3.09 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-04 | Ripresa | Cantor Fitzgerald | Neutral |
2025-03-04 | Downgrade | Needham | Buy → Hold |
2025-03-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
2025-03-03 | Downgrade | Stifel | Buy → Hold |
2025-02-10 | Downgrade | Canaccord Genuity | Buy → Hold |
2025-02-10 | Downgrade | Citigroup | Buy → Neutral |
2025-02-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
2025-02-10 | Downgrade | JP Morgan | Overweight → Neutral |
2025-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
2025-02-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2025-02-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2024-09-09 | Ripresa | Leerink Partners | Outperform |
2023-12-08 | Iniziato | Wells Fargo | Overweight |
2023-05-18 | Iniziato | Canaccord Genuity | Buy |
2023-04-13 | Iniziato | Robert W. Baird | Outperform |
2022-12-14 | Iniziato | Stifel | Buy |
2022-12-07 | Iniziato | JP Morgan | Overweight |
2022-09-01 | Iniziato | Citigroup | Buy |
2022-07-20 | Iniziato | SVB Leerink | Outperform |
2022-05-25 | Iniziato | Cantor Fitzgerald | Overweight |
2021-12-10 | Iniziato | Oppenheimer | Outperform |
2021-11-24 | Iniziato | RBC Capital Mkts | Outperform |
2021-11-03 | Iniziato | H.C. Wainwright | Buy |
2021-04-20 | Iniziato | BTIG Research | Buy |
2021-04-05 | Iniziato | Citigroup | Buy |
2020-06-29 | Iniziato | Citigroup | Buy |
2020-06-29 | Iniziato | Cowen | Outperform |
2020-06-29 | Iniziato | Needham | Buy |
2020-06-29 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Pliant Therapeutics Inc Borsa (PLRX) Ultime notizie
Pliant Therapeutics presents new fibrosis treatment data By Investing.com - Investing.com Canada
Pliant Therapeutics Presents Clinical and Preclinical Data at th - GuruFocus
Pliant Therapeutics presents new fibrosis treatment data - Investing.com
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference | PLRX Stock News - GuruFocus
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society ... - Eagle-Tribune
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference - GlobeNewswire
Breakthrough: Pliant's New Lung Disease Drug Outperforms Standard Treatment in Latest Clinical Data - Stock Titan
How Are Things Looking For Pliant Therapeutics Inc (NASDAQ: PLRX) For The Short Term? - Stocksregister
Cautious Hold Rating on Pliant Therapeutics Amid Clinical and Financial Uncertainties - TipRanks
Another Bay Area biotech company announces layoffs - MSN
Pliant Therapeutics Reports Q1 2025 Financial Results - TipRanks
Pliant (PLRX) Prepares to Release Topline Results from BEACON-IP - GuruFocus
Pliant (PLRX) Prepares to Release Topline Results from BEACON-IPF Trial | PLRX Stock News - GuruFocus
Pliant Therapeutics reports Q1 EPS (92c), consensus (62c) - TipRanks
Pliant Therapeutics (PLRX) Advances in Clinical Trials and Oncology Research | PLRX Stock News - GuruFocus
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Market Watch Highlights: Pliant Therapeutics Inc (PLRX) Ends on an Downturn Note at 1.43 - DWinneX
Pliant Therapeutics Cuts Workforce by Nearly Half - Powder & Bulk Solids
Bay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in value - MSN
Pliant cuts workforce by 45% following lung trial termination - Clinical Trials Arena
Pliant Therapeutics to cut 45% of workforce (PLRX:NASDAQ) - Seeking Alpha
Pliant Therapeutics (PLRX) Restructures to Prolong Financial Res - GuruFocus
Pliant Therapeutics Reduces Workforce as Part of Strategic Realignment - MarketWatch
Pliant Therapeutics (PLRX) Restructures to Prolong Financial Resources | PLRX Stock News - GuruFocus
Pliant Therapeutics announces workforce reduction By Investing.com - Investing.com India
Pliant Therapeutics announces workforce reduction - Investing.com
Pliant Therapeutics Announces Major Workforce Reduction - TipRanks
Pliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical Trials - Nasdaq
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations - GlobeNewswire
Pliant Therapeutics Slashes Nearly Half its Workforce While Awaiting Crucial IPF Drug Results - Stock Titan
You might want to take a look at Pliant Therapeutics Inc (PLRX) now - Sete News
Pliant Therapeutics Inc [PLRX] stock was sold by Coulie Bernard at the price of US$0.59 million - knoxdaily.com
Market Momentum: Pliant Therapeutics Inc (PLRX) Registers a 0.68 Increase, Closing at 1.48 - DWinneX
Stock Performance Spotlight: Cg Oncology Inc (CGON) Ends the Day at 26.94, Down by -3.68 - DWinneX
Pliant Therapeutics Inc (PLRX)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Legal & General Group Plc Grows Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - investchronicle.com
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - Louisiana First News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant ... - Bluefield Daily Telegraph
Pliant Therapeutics discovers new integrin αvβ1, αvβ6 and/or αvβ8 antagonists - BioWorld MedTech
Pliant Therapeutics Inc’s Market Journey: Closing Weak at 3.03, Down -1.62 - DWinneX
PLRXPliant Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Healthy Upside Potential: Pliant Therapeutics Inc (PLRX) - Sete News
Market Recap Check: Pliant Therapeutics Inc (PLRX)’s Positive Finish at 1.54, Up/Down 2.67 - DWinneX
Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - uspostnews.com
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Bought by JPMorgan Chase & Co. - Defense World
Pliant Therapeutics Inc Azioni (PLRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):